For laboratory research use only. Not for human or veterinary use. Read our research-use policy

Neuropeptides

VIP research peptide

Vasoactive intestinal peptide, a 28-residue C-terminally amidated neuropeptide that signals through the VPAC1 and VPAC2 receptors.

2 sizes · from $20.99 · 1 in stock · flat $24.95 US shipping per order

Sizes, prices and availability

VIP sizes and prices
SizeSKUStated purityBatch COAPriceAvailability
5 mg VIP5 Not yet provided Not yet provided $20.99 Out of stock
10 mg PP-VIP-10MG Not yet provided Not yet provided $34.99 In stock

Prices and stock are checked at build time and refreshed live in your browser. Orders are US only for a flat $24.95 shipping fee. Shipping details

About VIP

Vasoactive intestinal peptide (VIP) is a 28-residue neuropeptide, His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn, with an amidated C-terminus. It acts on two receptors, VPAC1 and VPAC2, which it shares with the related peptide PACAP (Nicole et al., 2000; Laburthe et al., 2007).

Nicole et al. (2000) replaced each residue of VIP in turn with alanine or glycine and report that changes at 14 of the 28 positions raised the binding or activation constant at VPAC1 more than 10-fold, and that modelling predicts a central alpha-helix from Val5 to Asn24 with random-coil termini. Using three substitutions (positions 11, 22 and 28) they obtained a VPAC1-selective agonist (more than 1,000-fold). Laburthe et al. (2007) review the structure and pharmacology of the VPAC1, VPAC2 and PAC1 receptors, and Moody and Jensen (2021) review the VIP and PACAP system in cell biology, cancer, central nervous system and inflammatory disorders.

What the published literature covers

  • Nicole et al. (2000) map the residues of VIP that interact with VPAC1 and VPAC2 by alanine scanning.
  • Laburthe et al. (2007) review class II G protein-coupled receptors for VIP and PACAP.
  • Moody and Jensen (2021) review the biology and pharmacology of VIP and PACAP (part 1), and their roles in central nervous system and inflammatory disorders (part 2).

Vial arithmetic

The peptide reconstitution calculator converts a vial size, diluent volume and target amount into concentration, syringe units and draws per vial. Volumes convert to syringe units with the syringe units converter. It does arithmetic only and does not suggest any amount.

FAQ

What is the VIP sequence?

HSDAVFTDNYTRLRKQMAVKKYLNSILN, 28 residues, with an amidated C-terminal asparagine (UniProt P01282, residues 125 to 152).

Which receptors does VIP act on?

VPAC1 and VPAC2, and it shares them with PACAP. PACAP additionally acts on the PAC1 receptor (Laburthe et al., 2007).

Why do the masses differ between sources?

The native peptide is C-terminally amidated (computed C147H238N44O42S, about 3325.9 g/mol). The PubChem entry for aviptadil lists the free acid, C147H237N43O43S, 3326.8 g/mol. The two differ by about 1 Da, which a mass spectrum can resolve.

What sizes of VIP does Covalume list?

Covalume lists VIP in 2 sizes: 5 mg, 10 mg. Each size shows its price and live stock status in the variants table on this page.

How is the purity of VIP documented?

Each listing shows the purity the supplier states, labelled (supplier), and the batch Certificate of Analysis field reads "Not yet provided" until a batch-specific document is on file. Our guide to reading a Certificate of Analysis explains what HPLC and mass-spectrometry results show.

References

  1. Nicole P, Lins L, Rouyer-Fessard C, et al. (2000). Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide. J Biol Chem 275:24003-12. PubMed 10801840 · DOI
  2. Laburthe M, Couvineau A, Tan V (2007). Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. Peptides 28:1631-9. PubMed 17574305 · DOI
  3. Moody TW, Jensen RT (2021). Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide [Part 1]: biology, pharmacology, and new insights into their cellular basis of action/signaling which are providing new therapeutic targets. Curr Opin Endocrinol Diabetes Obes 28:198-205. PubMed 33449573 · DOI
  4. Moody TW, Jensen RT (2021). Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide (Part 2): biology and clinical importance in central nervous system and inflammatory disorders. Curr Opin Endocrinol Diabetes Obes 28:206-213. PubMed 33481421 · DOI

Identity values are from PubChem (CID 16132300) and the cited papers; for linear peptides the mass was also checked against the sequence. Last updated 2026-11-18.

Related research peptides

From the research library